Information about Psychoactive Medication

Started by Kizzie, June 13, 2019, 12:13:36 AM

Previous topic - Next topic

Kizzie

MAPS (Multidisciplinary Association for Psychedelic Studies) - a 501(c)(3) non-profit research and educational organization that develops medical, legal, and cultural contexts for people to benefit from the careful uses of psychedelics and marijuana.

MDMA-assisted psychotherapy for treatment of PTSD: study design and rationale for phase 3 trials based on pooled analysis of six phase 2 randomized controlled trials, May 2019.  Note: This article concerns MDMA trials for PTSD vs Complex PTSD

Statement: Considerations for the Regulation and Decriminalization of Psychedelic Substances, May 31, 2019. By Natalie Lyla Ginsberg, M.S.W., and Ismail Lourido Ali, J.D.

Scientists are reclaiming psychedelics as "wonder drugs." Is it time to decriminalize them?,  June 6, 2019 - Video by Michael Tabb

Kizzie

TED talk by Rick Doblin, founder of MAPS (Multidisciplinary Association for Psychedelic Studies)"

"The Future of Psychedelic-assisted Psychotherapy"

Kizzie

Psychedelic Medicine Is Coming. The Law Isn't Ready - "A surprising resurgence of psychedelic research has produced its first FDA-approved treatment, with more likely on the way" by Matt Lamkin, July 31, 2019.

Excerpt:


The prospect of psychedelic drugs gaining approval as treatments will force a reckoning for our existing system of drug control. While current policies characterize any use of these substances as illicit abuse, acknowledging that these drugs may offer meaningful benefits will require more flexible approaches. Psychedelic medicine may prove to be the thin end of a wedge that moves drug policy away from the elusive goal of eradication in favor of more nuanced strategies that harness the benefits of psychotropic drugs while minimizing their risks.

Kizzie


Zorra

>>Checking In, Not Checking Out: Cannabis-Assisted Psychotherapy
May 23, 2018 Sara Ouimette, MA, posted in Mental Health
Counter to popular belief, cannabis can be an excellent tool for personal growth and insight. Many people in today's society are not utilizing cannabis's full potential. It's common to use a substance to escape pain, and cannabis's euphoric effect can be rather seductive for this reason. However, when used with careful intention, cannabis's ability to amplify and clarify sensations, emotions, and thoughts while simultaneously softening defenses makes it a wonderful psychotherapeutic facilitator.

Cannabis as Entheogen: Manifesting the God Within
Humanity's relationship with cannabis is thousands of years old. It is one of the most ancient and universal entheogens known to man. People all over the world have continually and consistently been drawn to the sacred states of mind that cannabis can produce. With current developments in research and legalization, cannabis is being recognized once again for its medicinal value. Here in Oakland, CA, where cannabis is legal, recreational and medicinal use are much more widely accepted. However, cannabis's role as a holy sacrament has been largely lost, and therefore so has its potential as a transformational tool. By changing our relationship to this plant into one that respects its power, we can begin to achieve greater self-awareness, insight, and liberation from painful emotional patterns.>>

https://psychedelic.support/resources/checking-in-not-checking-out/

Kizzie

Ketamine Clinicians Publish Ethical Guidelines to Raise Treatment Standards
by Ann Harrison, January 16, 2021 - Guidelines

A new paper published in the Journal of Psychedelic Psychiatry lays out guidelines that propose a standard of care for the growing number of clinicians providing ketamine for mental health indications. The authors of the paper note that despite the rapid expansion of these services, many providers of therapeutic ketamine do not have training in psychological or psychiatric treatment.

"The majority of ketamine providers draw from limited, if any, formal psychiatric or psychological training or experience, and provide in-office ketamine without psychiatric treatment planning or psychotherapy," write authors Dr. Wesley Ryan and Raquel Bennett PsyD.


So, if you are considering ketamine treatment be cautious and find out whether the clinician is properly trained medically and psychologically.

Kizzie

A new psychedelic-like drug AAZ-A-154 could treat  C/PTSD w/o causing hallucinogenic 'tripping'. Psychedelics have long shown promise for treating a host of mental illnesses & now scientists have ident a compound that provides only the benefits. https://www.goodnewsnetwork.org/uc-davis-aaz-a-154-psychadelic-like-no-hallucinations/

Kizzie

Two research studies from Dolly Vee that demonstrate the positive treatment effects of psychedelics on autoimmune conditions.

Nkadimeng, S. M., Steinmann, C., & Eloff, J. N. (2021). Anti-Inflammatory Effects of Four Psilocybin-Containing Magic Mushroom Water Extracts in vitro on 15-Lipoxygenase Activity and on Lipopolysaccharide-Induced Cyclooxygenase-2 and Inflammatory Cytokines in Human U937 Macrophage Cells. Journal of inflammation research, 14, 3729–3738. https://doi.org/10.2147/JIR.S317182

This study aimed at investigating the anti-inflammatory effects of four psilocybin-containing mushrooms (Panaeolus cyanescens, Psilocybe natalensis, Psilocybe cubensis and Psilocybe cubensis leucistic A+ strain) from genus Panaeolus and Psilocybe for the first time in vitro on 15-LOX activity and also on lipopolysaccharide (LPS)-induced inflammation in human U937 macrophage cells. The study suggested that the hot-water extracts of the four psilocybin-containing magic mushrooms have potential anti-inflammatory effects executed by down-regulating pro-inflammatory mediators.

Thompson, C., & Szabo, A. (2020). Psychedelics as a novel approach to treating autoimmune conditions. Immunology letters, 228, 45–54. https://doi.org/10.1016/j.imlet.2020.10.001

This literature review explores existing evidence that psychedelic compounds may offer a potential novel application in the treatment of pathologies related to autoimmunity. We propose that psychedelics hold the potential to attenuate or even resolve autoimmunity by targeting psychosomatic origins, maladaptive chronic stress responses, inflammatory pathways, immune modulation and enteric microbiome populations.